These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7045444)

  • 21. Dilazep prevents glomerulosclerosis in accelerated Masugi nephritis in the rat.
    Nakazawa K; Moriya T; Kasai S; Yamazaki T; Komiyama Y; Shigematsu H; Akiba T; Koga T
    Nihon Jinzo Gakkai Shi; 1993 Apr; 35(4):329-35. PubMed ID: 8341008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Functional analysis for dysfibrinogenemias, Toyama and Adachi, which have a mutation of Aalpha16Arg-->His (CGT-->CAT) with aberrant fibrinopeptide A release].
    Soya K; Takezawa Y; Terasawa F; Okumura N
    Rinsho Byori; 2012 Jun; 60(6):499-505. PubMed ID: 22880226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural distortion of glomerular capillary loops in the chronic phase of rat Masugi nephritis.
    Takizawa J; Shigematsu H; Kondo Y
    Lab Invest; 1979 May; 40(5):519-28. PubMed ID: 439855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hypofibrinogenemia caused by long-term administration of hemocoagulase: three cases report and literature review].
    Wang Z; Li J; Cao L; Yu Z; Bai X; Ruan C
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):50-2. PubMed ID: 24602733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defibrinogenation by batroxobin and acylated batroxobin in rats.
    Richter M; Paintz M; Stürzebecher J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):147-51. PubMed ID: 2459010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On platelet fibrinogen in plasma defibrinogenated dogs and in uremic patients before and after hemodialysis.
    Johnsson H
    Thromb Res; 1975 Jul; 7(1):161-74. PubMed ID: 1154334
    [No Abstract]   [Full Text] [Related]  

  • 27. Glomerular fibrinolytic activity during nephrotoxic nephritis.
    Giroux L; Verroust P; Morel-Maroger L; Delarue F; Delauche M; Sraer JD
    Lab Invest; 1979 Apr; 40(4):415-22. PubMed ID: 431041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Technique and laboratory control of subcutaneously administered defibrase.
    Martin M; Auel H
    Thromb Res; 1976 Jul; 9(1):59-65. PubMed ID: 960062
    [No Abstract]   [Full Text] [Related]  

  • 29. Plasma administration to defibrinogenated dogs during extracorporeal circulation.
    Berglin E; Hansson HA; William-Olsson G
    Artif Organs; 1979 Feb; 3(1):80-5. PubMed ID: 435130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crescentic type nephritis induced by anti-glomerular basement membrane (GBM) serum in rats.
    Ito M; Yamada H; Okamoto K; Suzuki Y
    Jpn J Pharmacol; 1983 Dec; 33(6):1145-54. PubMed ID: 6668763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Masugi nephritis in T cell-depleted state. Influence of adult thymectomy and anti-thymocyte serum.
    Oite T
    Acta Pathol Jpn; 1979 May; 29(3):333-45. PubMed ID: 377909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defibrinogenating enzymes.
    Bell WR
    Drugs; 1997; 54 Suppl 3():18-30; discussion 30-1. PubMed ID: 9360849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effects of heparin, urokinase, and ancrod on intraglomerular coagulation induced in progressive Masugi nephritis.
    Dohi K; Fujioka M; Nakamoto Y
    Acta Pathol Jpn; 1982 Nov; 32(6):1047-52. PubMed ID: 6760667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in mRNA levels of fibrinogen subunit polypeptides in rats defibrinogenated with batroxobin.
    Iwai S; Okazaki M; Kiuchi Y; Oguchi K
    Thromb Res; 1999 Dec; 96(6):421-6. PubMed ID: 10632464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation of oxygen radicals and formation of fibrin thrombi in glomerular capillaries of rats with nephrotoxic nephritis.
    Ito S; Sugisaki T; Soezima K
    Nihon Jinzo Gakkai Shi; 1989 Feb; 31(2):171-7. PubMed ID: 2739116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heparin therapy in anti-basement membrane nephritis.
    Bone JM; Valdes AJ; Germuth FG; Lubowitz H
    Kidney Int; 1975 Aug; 8(2):72-9. PubMed ID: 1160229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Release of plasminogen activator by batroxobin.
    Klöcking HP; Hoffmann A; Markwardt F
    Haemostasis; 1987; 17(4):235-7. PubMed ID: 3305231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Role of natural killer cells in the antimetastatic effect of defibrinogenation with batroxobin].
    Shibuya M; Kawachi S; Aoyama A; Murata A; Baba M; Hirata K; Ohtsuka M; Matsusaka M; Yano T; Niitani H
    Gan To Kagaku Ryoho; 1987 Jul; 14(7):2286-92. PubMed ID: 3300562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic fate of 125I-labeled batroxobin in rats and dogs.
    Sugai K; Imamura Y; Mihashi S; Mori N; Baba S
    J Toxicol Sci; 1986 Aug; 11(3):155-67. PubMed ID: 3540318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Defibrinogenation as an alternative to heparinization during prolonged extracorporeal circulation in the dog.
    Berglin E; Hansson HA; Teger-Nilsson AC; William-Olsson G
    Thromb Res; 1976 Jul; 9(1):81-93. PubMed ID: 960064
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.